Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

Chung CH, Aulino J, Muldowney NJ, Hatakeyama H, Baumann J, Burkey B, Netterville J, Sinard R, Yarbrough WG, Cmelak AJ, Slebos RJ, Shyr Y, Parker J, Gilbert J, Murphy BA
Ann Oncol. 2010 21 (4): 864-870

PMID: 19850643 · PMCID: PMC2844946 · DOI:10.1093/annonc/mdp390

MeSH Terms (20)

Antineoplastic Combined Chemotherapy Protocols Biomarkers, Pharmacological Boronic Acids Bortezomib Carcinoma, Squamous Cell Docetaxel Female Gene Expression Regulation, Neoplastic Head and Neck Neoplasms Humans Male Middle Aged Neoplasm Metastasis NF-kappa B Pyrazines Recurrence Signal Transduction Survival Analysis Taxoids Treatment Outcome

Connections (4)

This publication is referenced by other Labnodes entities:

Links